We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.
Company profile
Ticker
GTHP
Exchange
Website
CEO
Gene Cartwright
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical ...
Former names
SPECTRX INC
SEC CIK
Corporate docs
IRS number
582029543
GTHP stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Departure of Directors or Certain Officers
9 Mar 23
EFFECT
Notice of effectiveness
26 Jan 23
CORRESP
Correspondence with SEC
23 Jan 23
UPLOAD
Letter from SEC
23 Jan 23
S-1
IPO registration
13 Jan 23
RW
Registration withdrawal request
2 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Entry into a Material Definitive Agreement
15 Sep 22
Latest ownership filings
SC 13G/A
Auctus Fund Management LLC
14 Feb 23
SC 13G
Auctus Fund Management LLC
24 Oct 22
SC 13G
Rosalind Advisors, Inc.
6 Jul 22
SC 13D
Guided Therapeutics Inc
25 May 18
3
Lynne H Imhoff
25 May 18
SC 13G
Guided Therapeutics Inc
9 Mar 17
3
Richard P. Blumberg
18 Nov 16
SC 13G
Guided Therapeutics Inc
18 Apr 16
SC 13G/A
Guided Therapeutics Inc
7 Oct 15
SC 13G
Guided Therapeutics Inc
5 Oct 15
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm | 1.84 mm |
| Cash burn (monthly) | 158.67 k | (no burn) | 281.00 k | 311.00 k | 166.33 k | 149.83 k |
| Cash used (since last report) | 310.33 k | n/a | 549.60 k | 608.28 k | 325.33 k | 293.06 k |
| Cash remaining | 1.53 mm | n/a | 1.29 mm | 1.23 mm | 1.51 mm | 1.54 mm |
| Runway (months of cash) | 9.6 | n/a | 4.6 | 4.0 | 9.1 | 10.3 |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|